HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis

Press/Media

Period	9 Mar 2021

Media coverage

Title	HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
Media name/outlet	BioForward
Country/Territory	United States
Date	9/03/21
URL	https://www.bioforward.org/humira-adalimumab-receives-fda-approval-to-treat-pediatric-patients-living-with-moderately-to-severely-active-ulcerative-colitis/
Persons	Marla Dubinsky